Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
16.33
+0.26 (1.62%)
At close: Jun 26, 2026, 4:00 PM EDT
16.11
-0.22 (-1.32%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Viatris Employees
Viatris had 30,000 employees as of December 31, 2025. The number of employees decreased by 2,000 or -6.25% compared to the previous year.
Employees
30,000
Change (1Y)
-2,000
Growth (1Y)
-6.25%
Revenue / Employee
$485,420
Profits / Employee
-$9,883
Market Cap
19.02B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30,000 | -2,000 | -6.25% |
| Dec 31, 2024 | 32,000 | -6,000 | -15.79% |
| Dec 31, 2023 | 38,000 | 1,000 | 2.70% |
| Dec 31, 2022 | 37,000 | 0 | - |
| Dec 31, 2021 | 37,000 | -8,000 | -17.78% |
| Dec 31, 2020 | 45,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,029 |
| Teva Pharmaceutical Industries | 33,950 |
| Dr. Reddy's Laboratories | 27,527 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
VTRS News
- 5 weeks ago - Viatris price target raised to $22 from $17 at Barclays - TheFly
- 5 weeks ago - Viatris says FDA accepts for review NDA for MR-107A-02 - TheFly
- 5 weeks ago - U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - PRNewsWire
- 6 weeks ago - Viatris Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Viatris price target raised to $20 from $18 at Truist - TheFly
- 7 weeks ago - Viatris price target raised to $18 from $17 at JPMorgan - TheFly
- 7 weeks ago - Viatris to Present at the Bank of America Securities 2026 Healthcare Conference - PRNewsWire
- 7 weeks ago - Viatris beats quarterly estimates on China strength, branded drug sales - Reuters